Our multi-specific immuno-oncology drug ND021 holds the promise to outperform first-generation checkpoint modulators in terms of safety and efficacy.
Pipeline04
Partnered Regionally
Discovery
Preclincal PoC
IND-enabling studies
Phase I
Partner
Fully Owned by Numab
NM32-2668
(aROR1/CD3/hSA)
Oncology
Partnered Globally
Research
Development
Partner
NM21-1480 – Immuno-oncology
NM26-2198 – Inflammation
NM32-2668 – Immuno-oncology
NM28-2746 – Immuno-oncology
Multispecific Immuno-Oncology Products
NM21-1480 – Immuno-oncology
NM21-1480 is a next-generation multi-specific cancer therapeutic that simultaneously targets the tumor-immunity suppressive PD(L)-1 pathway and the tumor-immunity stimulatory 4-1BB/CD137 pathway. Targeting these two clinically validated pathways in a combinatorial approach is expected to provide patients suffering from a broad range of cancer types with a unique novel treatment opportunity characterized by an improved benefit-to-risk profile as compared to current standard of care as well as other combinatorial immunotherapy approaches currently in clinical development. The differentiating profile of NM21-1480 is based on its molecular design as a monovalent trispecific antibody fragment aimed at highly effective, while only local activation of a tumor-directed specific immune response. NM21-1480 is currently being tested in a phase 1/2 clinical study (NCT04442126) in patients with advanced solid tumors. Numab develops this therapy together with its Chinese partner CStone Pharmaceuticals.
Poster presentation at AACR Annual Meeting 2020
Poster presentation at AACR Annual Meeting 2022
Expanded Access Policy
Numab Therapeutics AG (Numab) is committed to developing multi-specific antibody-based therapeutics for patients with serious cancers. Numab aims to provide access to our investigational therapies primarily through ongoing clinical trials.
“Expanded Access” refers to the use of an investigational therapy for potential treatment of a serious condition in a patient, where such use is not within a clinical trial setting. The US Food and Drug Administration has set forth guidelines when considering expanded access. They include:
- The disease or condition must be serious or immediately life-threatening with no adequate alternative therapy options available;
- There must be sufficient evidence that, based on available safety and efficacy information, the potential benefit to the patient would likely outweigh any potential risks; and
- Provision of the investigational drug for expanded access use will not interfere with, or delay, ongoing or planned clinical development programs, completion of which would enable therapy access for many more patients.
Learn more about its unique mode-of-action
×
NM26-2198 – Inflammation
ND026 is a multi-specific immunomodulatory therapy for inflammatory disorders. Numab develops this program together with its Japanese partner Kaken Pharmaceutical Co., Ltd.
NM32-2668 – Immuno-oncology
NM32-2668 is a tri-specific anti-ROR1/CD3/HSA antibody based on our scMATCH3 format. NM32-2668 induces T cell-mediated lysis of tumors expressing Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). Binding to human serum albumin (HSA) prolongs the half-life of the molecule in circulation and supports a convenient dosing scheme. ROR1 is overexpressed on a variety of difficult to treat tumors, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), triple-negative breast cancer (TNBC), lung cancer, and ovarian cancer. ROR1-expressing hematologic and solid tumors display a high potential for self-renewal, increased survival, and migration, and are associated with poor outcomes.
NM28-2746 – Immuno-oncology
NM28 consists of four stabilized and humanized antibody variable domain fragments directed against MSLN, CD3, and human serum albumin (HSA). MSLN is commonly expressed in a variety of tumor cells, including mesothelioma, lung, biliary, ovarian, breast, and pancreatic cancer. NM28 is designed to be resistant to the scavenging effect of soluble MSLN shed from tumor cells to improve efficacy, and to discriminate between tumor cells and MSLN-expressing normal cells to improve safety when compared to monovalent T cell engaging approaches targeting MSLN. Numab develops this therapy together with its Chinese partners 3SBio / Sunshine Guojian.
Multispecific Immuno-Oncology Products
Numab is developing multiple proprietary immuno-oncology programs utilizing our versatile, multi-specific MATCH platform. We are combining immune effector functions, immune-checkpoint antagonism, and cancer-specific targeting to create highly innovative, multi-functional drug candidates designed to bring significant improvement to the lives of cancer patients.
